Condition 1: Sarcopenia. Condition 2: Intrinsic capacity. Muscle wasting and atrophy, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: 33 elderly receive one tablet of 250 mg of magnesium supplement and 1000 mg of omega 3(120 mg EPA and 180 mg DHA) daily for 8 weeks each. Intervention 2: Control gr
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to 84 Years
Inclusion criteria
Inclusion criteria: Complete and sign informed consent Age 60-84 years Diagnosis of possible sarcopenia according to update of Asian Working Group for Sarcopenia (AWGS) (hand grip strength less than 28 kg in men and less than 18 kg in women) Impaired intrinsic capacity according to the first step of ICOPE guidelines of the World Health Organization Required no or some support with self-care (feeding, bathing, dressing, toileting). Taking any supplements containing magnesium and omega-3 during the last 2 months Taking any supplements containing more than 100 mg magnesium
Exclusion criteria
Exclusion criteria: Acute cardiovascular diseases, acute infection, and acute cerebrovascular disease Severe cardiac, liver, kidney dysfunction, autoimmune Uncontrolled diabetes Dementia, Parkinsons disease, and mental illnesses unable to provide informed consent because of aphasia, deafness, and blindness Physically-handicapped, disability, and use of a wheelchair or walker Taking hormonal drugs smoking Acute illness (cold, corona and any other viral-bacterial-fungal disease) Taking steroidal and non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics, laxatives and laxatives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Muscle strength. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Handgrip strength.;Muscle function. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Short Physical Performance Battery (SPPB).;Muscle mass. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Bioelectrical Impedance Analysis (BIA).;Inflammation. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of CRP and ESR in serum.;Intrinsic capacity index. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Short Physical Performance Battery (SPPB), Mini-mental state examination(MMSE), Patient Health Questionnaire-9(PHQ-9), WHISPER test, WHO simple eye chart, Mini nutritional assessment (MNA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Frailty. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The Fried phenotype (FP). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Reza Vafa
Iran University of Medical Sciences
Outcome results
None listed